News
GRFS
7.94
+1.40%
0.11
Weekly Report: what happened at GRFS last week (0727-0731)?
Weekly Report · 4d ago
Grifols Reshapes Board and Committee Leadership After Director Resignation
TipRanks · 07/30 15:17
Grifols names Joanna Susan Le Couilliard as audit committee chair
PUBT · 07/30 06:53
Grifols says EXCELL Phase 3 trial timeline not ‘new development or a delay’
TipRanks · 07/29 17:55
Grifols posts transcript of Q2 2026 earnings call
PUBT · 07/29 14:57
FOXO unit Vector BioSource agrees to buy four Grifols blood collection centers in US asset deal
PUBT · 07/29 12:33
Grifols Half-Year 2026 Results: Profit Jumps as Refinancing Bolsters Balance Sheet
TipRanks · 07/29 10:32
Grifols (GRFS) Q2 2026 Earnings Call Transcript
NASDAQ · 07/29 01:12
Grifols Earnings Call Highlights Biopharma Momentum, Cash Gains
TipRanks · 07/29 00:19
Grifols H1 Profit Rises 29%; Backs FY26 Outlook
NASDAQ · 07/28 17:37
Grifols H1 FY26 profit falls 43.39% to EUR 227.51 million; net sales drop 2.79% to EUR 3.57 billion
PUBT · 07/28 15:43
Here are the major earnings before the open Tuesday
Seeking Alpha · 07/27 22:00
FOXO unit Vector BioSource agrees to buy four Grifols blood collection centers for $3.5 million plus up to $1 million earnout
PUBT · 07/27 20:16
Accendra Health names Agnes Ansay chief procurement officer
PUBT · 07/27 20:11
Weekly Report: what happened at GRFS last week (0720-0724)?
Weekly Report · 07/27 10:27
Spanish stocks - Factors to watch on July 27
Reuters · 07/27 06:20
Grifols Reports Next Week With Restructuring Questions Still Unanswered
Barchart · 07/24 16:02
Weekly Report: what happened at GRFS last week (0713-0717)?
Weekly Report · 07/20 10:23
Oakmark International Small Cap Fund Q2 2026 Portfolio Activity
Seeking Alpha · 07/16 19:24
More
Webull provides a variety of real-time GRFS stock news. You can receive the latest news about Grifols S A through multiple platforms. This information may help you make smarter investment decisions.
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.